Celgene: FDA Approves Otezla for 3rd indication

Celgene Corp. (CELG) said the U.S. Food and Drug Administration approved Otezla 30 mg twice daily for adults with oral ulcers associated with Behcet’s Disease.

Behcet’s Disease is a rare, chronic, multisystem inflammatory disease that is difficult to treat, Celgene said. Otezla reduced the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study.

Otezla is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis, the company said.

https://www.marketscreener.com/CELGENE-CORPORATION-8736/news/Celgene-Says-FDA-Approves-Otezla-for-Oral-Ulcers-in-Behcet-s-Disease-28930277/